United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - xyzal is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. xyzal is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of xyzal is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of xyzal, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)] . patients with end-stage renal disease (clcr <10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - enter section text here xyzal® is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older. xyzal is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 months of age and older. xyzal is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of xyzal is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of xyzal, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr less than 10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function enter section text here pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction s

Malta - English - Medicines Authority

ucb pharma sa 60 allee de la recherche, b-1070 brussels, belgium - levocetirizine dihydrochloride - oral solution - levocetirizine dihydrochloride 0.5 mg/ml - antihistamines for systemic use

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - see ingredients - each tablet contains levocetirizine dihydrochloride 5,0 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - levocetirizine dihydrochloride - film-coated tablet - 5 milligram(s) - piperazine derivatives; levocetirizine

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - levocetirizine dihydrochloride - film coated tablet - 5 milligram - levocetirizine

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - levocetirizine dihydrochloride - film-coated tablet - 5 milligram(s) - piperazine derivatives; levocetirizine

Malta - English - Medicines Authority

ucb pharma sa 60 allee de la recherche, b-1070 brussels, belgium - levocetirizine dihydrochloride - film-coated tablet - levocetirizine dihydrochloride 5 mg - antihistamines for systemic use

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - levocetirizine dihydrochloride - oral tablet - 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - levocetirizine dihydrochloride - oral solution - 0.5 milligram(s)/millilitre - piperazine derivatives; levocetirizine